+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB
Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

News U1

02 Mar

U1 NANBIOSIS - Public-Private collaboration to Investigate New Inhibitors Against Pain
Public-Private collaboration to Investigate New Inhibitors Against Pain

Unit 1 of NANBIOSIS, together with Synchroton Alba and the pharmaceutical ESTEVE jointly investigate the mechanisms of new inhibitors against pain ESTEVE, a chemical – pharmaceutical group leader in Spain and with an important international presence, has developed new inhibitors against pain. Collaboration with scientific expertise of the Protein Production Platform and the ALBA Synchrotron will allow studyingthe interaction of these inhibitors with its potential target. The results of the research may help to the better understanding of the effects of the inhibitors and will provide key information to improve their properties. The  Protein Production Platform (Unit 1 of NANBIOSIS) is in[...]

28 Jun

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”
“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”

Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358 “a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo,  P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido,[...]

18 Apr

Nanbiosis_Unit 1 of NANBIOSIS certified with ISO 9001- 2008
Unit 1 of NANBIOSIS certified with ISO 9001: 2008

Unit 1 of NANBIOSIS, Production Platform Protein (PPP) at the Autonomous University of Barcelona, ​​directed by Dra. Neus Ferrer and coordinated by Professor Antonio Villaverde, provides the service of production and purification of recombinant proteins in different systems expression, microbial and non-microbial. This service was audited last November, based on the UNE EN ISO 9001: 2008 AENOR, who has issued a favourable certification report. The requirements of this standard cover all aspects of management. This certification will expand and consolidate the service  that the Unit 1 of NANBIOSIS is giving to companies and public sector researchers and facilitate their integration[...]

31 Mar

Nanbiosis Ibb news
MEMBERS OF THE IBB WILL INVESTIGATE THE EARLY DIAGNOSIS OF PARKINSON

Researchers from the Folding and Conformational Diseases Group at the Institute of Biotechnology and Biomedicine Group are part of the European project Neuromed to develop molecules and detect biomarkers of this disease before the signs of neurodegeneration become evident. The Neuromed project is led by the University of Zaragoza and aims to design molecules, drugs and new diagnostic tools early for three neurodegenerative diseases in which defective proteins are involved: Parkinson’s disease and two rare diseases, phenylketonuria and protein TTR Amyloidosis. The coordination of the Parkinson’s research line will be directed, from the IBB, by Salvador Ventura, principal researcher and[...]

U1-Protein Production Platform - PPP
Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

News U2

17 Apr

Unit 2 Nanbiosis have signed an agreement with a Belgian Enterprise.

U2 unit of Nanbiosis (Custom antibody service) has recently signed a 3-year contract with UNISENSOR S.A. (Liege, Belgium) for producing on a high scale a collection of immunoreagents used in their diagnostic kits. UNISENSOR S.A. is a SME biotech company that develops on site diagnostic systems for food safety. Unit 2 of NANBIOSIS, coordinated by Nb4D-CSIC holds a research collaboration for more than 7 years developing new bioproducts and transferring knowledge to UNISENSOR S.A. As result of the collaboration several diagnostic kits are nowadays in the market, consequently this contract has been signed with the aim to supply UNISENSOR S.A. with immunoreagents for their[...]

19 Dec

NANBIOSIS in three projects funded by CaixaIMPULSE.
NANBIOSIS in three projects funded by CaixaIMPULSE

La Caixa has just presented the twenty projects selected by CaixaImpulse in a call with more than 70 proposals from different research centres, hospitals and universities. CaixaImpulse is an initiative unique in Spain that aims to boost research in biotechnology and life sciences to develop projects that generate value in society. Among the selected projects there are two coordinated by NANBIOSIS researchers: Pseudomonas aeruginosa diagnosis led by Miriam Corredor Sánchez (Unit 2 of NANBIOSIS) and ISCHEMSURG, led by Monica Mir (Unit 7 of NANBIOSIS). In addition, the project ExoLiver, in which participates Rosa Villa and the research group coordinating Unit 8[...]

06 Dec

Unit 2 of NANBIOSIS participates in the FoodSmartPhone project of Marie Sklodowska Curie.
Unit 2 of NANBIOSIS participates in the FoodSmartPhone project of Marie Sklodowska Curie.

The Nb4D group of CSIC, coordinator of Unit 2 of NANBIOSIS led by Pilar Marco has joined the consortium for the FoodSmartPhone project funded by the Marie Sklodowska Curie Research Program. The Marie Sklodowska-Curie Actions (MSCA) support training in research and professional development aimed at innovation skills. The objective of the project is to develop a smartphone-based diagnostic and detection tool for simplified quick pre-selection of food quality and safety parameters. This is because food safety and quality tests are currently inefficient, expensive and ineffective and can not guarantee food safety for all consumers or prevent possible incidents of food[...]

20 Apr

Nanbiosis_U2_Nanobiotechnology for Diagnostics Group awarded with TECNIO grant to encourage Technology Transfer
Nanobiotechnology for Diagnostics Group awarded with TECNIO grant to encourage Technology Transfer

The Nanobiotechnology for Diagnostics Group (Nb4D), the host group for the Custom Antibody Service of Unit 2 of NANBIOSIS was recently awarded with grant that ACCIÓ provides to groups who are seeking to be accredited with the TECNIO seal. The aim is to help define and boost their action plans for technology transfer. These grants are destined at financing for 3 years the integration of these groups in the UAB-CEI sphere of the TECNIO network. The group will use this finance for activities related to the execution during the first year of a growth plan to increase their technology transfer[...]

U2-Custom Antibody Service (CAbS)
Read More

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@irbbarcelona.org
  • Scientific Coordinator: Dr. Miriam Royo mroyo@pcb.ub.cat
  • Entities: Parc Cientific de Barcelona (PCB) & Universidad de Barcelona (UB)
  • Address: Baldiri Reixac 10, 08028, Barcelona, Spain
  • Phone: +34 934 037 122
  • Web:PCB – UB
PCB
Order request

Description

This Unit is coordinated by the Peptides and Nanoparticles Group at the Parc Científic de Barcelona (PCB) and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the PCB with an occupy area of 5.000m2.

News U3

28 Jun

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”
“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”

Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358 “a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo,  P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido,[...]

U3-Synthesis of Peptides Unit
Read More

U4. Biodeposition and Biodetection Unit

Ciber bbn

U4. Biodeposition and Biodetection Unit

  • Scientific Director: Prof. Laura Lechuga laura.lechuga@icn2.cat
  • Scientific Coordinator: Dr. MªCarmen Estevez mcarmen.estevez@icn2.cat
  • Entities: Research Center on Nanoscience and Nanotechnology CIN2 & CSIC
  • Address: Campus Bellaterra, 08193 Cerdanyola del Vallés, Barcelona, Spain
  • Service Contact mail: nanob2a@icn2.cat
  • Phone: +34 937 374 617
  • Web: CIN2
CIN2_U4 CSIC
Order request

Description

Located at the Research Center onNanoscience and Nanotechnology(CIN2), CSIC, at the campus of Universidad Autónoma de Barcelona (UAB) the Biodeposition Unit consists of a versatile and automated molecular printer that can dispense minute volumes of solutions (from atto to femtoliter volumes) on a wide variety of surfaces to create user-defined patterns of spots or lines with high spatial resolution. The system is suitable for the functionalization of biosensors with any kind of biomolecule, nanoparticles, graphene or other nanostructures,for surface patterning for cell culture, or for the preparation of micro/nanoarrays, among other applications. The laboratory also harbors a Surface Plasmon Resonance (SPR) service. The Unit is coordinated by Prof. LauraM. Lechuga, group leader from the Nanobiosensorsand Bioanalytical Applications Group (nanoB2A) at CIN2-CSIC.

News U4

04 May

Laura Lechuga in the fight against cancer

Dr. Laura Lechuga, Scientific Director of Unit 4 of NANBIOSIS is highlighted in Cinco Días. Elpais Economía  for its fight against cancer and, in particular, for the device developed with its team to detect the disease in matter of minutes “Have you ever wondered why glucose meters are so smart that they just measure sugar? The answer is that they carry specific proteins that only interact with sugar, “explains the doctor.  The same idea lies in the device designed by Laura Lechuga and her research group “With a minimum sample of the patient, it is possible to detect the presenc[...]

06 Feb

A multiplexing nanophotonic biosensor for cancer diagnosis
A multiplexing nanophotonic biosensor for cancer diagnosis

The group Biosensors and bio-analytic applications, led by Laura Lechuga,​ coordinator of Unit 4 of NANBIOSIS, has developed a methodology through a nano-photonic sensor (known as bimodal waveguide interferometer) capable of quantifying, directly and mark-free, the different messenger RNA isoforms generated by alternative splicing. The expertise in biodeposition and biodetection systems of Lechuga’s group has permitted a thorough analytical study and optimization of the methodology, achieving not only total selectivity, but also excellent levels of sensitivity and reproducibility, and obtaining the lowest levels of detection in direct detection of messenger RNA isoforms generated by this mechanism without the need for PCR amplification (polymerase chain reaction). T[...]

19 Dec

Laura Lechuga received the Physics, Innovation and Technology Prize
Laura Lechuga received the Physics, Innovation and Technology Prize

On December 14th, the Physics Awards ceremony was held at the BBVA Foundation’s headquarters, organized by the Spanish Royal Society of Physics (RSEF) and the BBVA Foundation, that each year select the most relevant achievements of Spanish physics. On this occasion the achievements of nanoscience have been recognized and it has been highlighted the power of physics to expand the territory of the known universe and the role of scientists as a core element of social progress. Professor Laura Lechuga, Scientific Director of Unit 4 of NANBIOSIS received the Physics, Innovation and Technology Prize was the only woman awarded. Lechuga[...]

24 Oct

Physics Prize of the Royal Spanish Society of Physics (RSEF) to Laura Lechuga
Physics Prize of the Royal Spanish Society of Physics (RSEF) to Laura Lechuga

Laura M. Lechuga, Scientific Director of the Unit 4 of NANBIOSIS has won the Physics Prize of the Royal Spanish Society of Physics (RSEF) -Foundation BBVA 2016 in the form of Physics, Innovation and Technology, endowed with 8,000 euros. Physics Awards recognize this year to researchers who have revealed the potential of the “nanoworld” to create new materials and fight disease. The jury highlighted her “excellent track record as a scientist, technologist and innovative” in the field of biosensor devices. “Prof. Lechuga – emphasizes the jury- has managed to walk the path from idea to product with great success. Her[...]

03 Oct

Laura Lechuga, Scientific Director of the Unit 4 of NANBIOSIS in the Spanish Selection of Science.
Laura Lechuga, Scientific Director of the Unit 4 of NANBIOSIS in the Spanish Selection of Science.

The selection of the best Spanish researchers in 2016 is an initiative of the magazine QUO to disseminate the work of scientists. The jury formed by eight eminent scientists (Amils, Ainhoa Goni, Emilio Lora-Tamayo, Vladimir de Semir, Fernando Peláez, Antonio Calvo, Pilar López and Manuel Toharia, has chosen the twelve scientists of international prestige who will form the Spanish National Science 2016: – Pedro Cavadas, plastic surgeon specializing in transplants – Mariano Barbacid, a biochemist at the National Cancer Research Centre (CNIO) – Susana Marcos, director of the Institute of Optics ‘Daza Valdes’ CSIC – Alberto Ruiz Jimeno, founder of[...]

26 Aug

Nanotechnology bio applications in the clinical diagnosis II biosensor BiMW for the early diagnosis of bacterial infections in cirrhotic patients
Nanotechnology bio applications in the clinical diagnosis II: biosensor BiMW for the early diagnosis of bacterial infections in cirrhotic patients

The peritonitis bacterial spontaneous is an infection of the fluid ascetic that has high incidence in cirrhotic patients and is associated with a high mortality. In such situation, a diagnosis early is essential for the survival of the patient. However, the identification of the causative pathogen of infection is based currently on cultivation methods that are slow and laborious. A research coordinated by the Group of Nanobiosensors and Bioanalytical applications of the CIBER-BBN, which coordinates Unit 4 of NANBIOSIS led by Laura Lechuga, has presented the development of a biosensor interferometric based in guides bimodal (BiMW), capable of identify and[...]

25 Aug

Nanotechnology bio applications in the clinical diagnosis nanoplasmodic biosensor device for the early diagnosis of colorectal cancer
Nanotechnology bio applications in the clinical diagnosis: nanoplasmodic biosensor device for the early diagnosis of colorectal cancer

The group of Nano-biosensors and Bioanalytical applications of CIBER-BBN which coordinates Unit 4 of NANBIOSIS directed by Dr. Laura Lechuga, has led the final preparations of a technology with potential application in the early diagnosis of colorectal cancer, based in the detection of specific biomarkers in blood. The nanoplasmonic biosensor based on LSPR (Localized Surface Plasmon Resonance) is generated on structured surfaces of nano discs of gold, that allow monitoring of biological interactions in real time and without the need of markers. The nanoplasmonic biosensor allows analysis of human samples in a few minutes, without requiring reagents or additional instrumentation.[...]

U4-Biodeposition and Biodetection Unit
Read More

U5. Rapid Prototyping Unit

Ciber bbn

U5. Rapid Prototyping Unit

  • Scientific Director: Prof. Elisabeth Engel elisabeth.engel@upc.edu
  • Scientific Coordinator: Miguel Angel Mateos mamateos@ibecbarcelona.eu
  • Entities: Biomaterials for Regenerative Therapies Group & Intitute of Bioengineering of Catalonia (IBEC)
  • Address: C/BaldiriReixac 15-21, 08028, Barcelona, Spain
  • Phone: +34 934 039 735
  • Web: IBEC
IBEC
Order request

Description

This facility is headed by Dr. Elisabeth Engel, PI of the Biomaterials for Regenerative Therapies Group at the Institute for Bioengineering of Catalonia (IBEC) and counts with a laboratory equipped to produce 3D structures of different materials. This system allows the fabrication of 3D porous scaffolds of defined geometry and porosity for tissue engineering applications. Dispensing and locating cells in specific positions on defined substrates is also possible due to the high precision levels of this tool.

News U5

28 Feb

3D printing biocompatible hydrogels

  Researchers of Unit 5 of NANBIOSIS, in collaboration with colleagues from the University of Montpellier, have laid the groundwork for faster advances in 3D printing for regenerative medicine by creating a system of ink and matrices that offers a solid basis for tissue regeneration. Due to their high water content, hydrogels are highly attractive biomaterials for 3D printing as efficient ‘surrogates’ for the extracellular matrix, onto which cells can be cultured. However, while they are relatively easy to produce using a method called extrusion printing, their stability and structural integrity can weaken when they’re in contact with biological fluids[...]

21 Dec

EIT Health Spain awards the best innovation and entrepreneurship projects
EIT Health Spain awards the best innovation and entrepreneurship projects

Elisabeth Engel, Scientific Director of Unit 5 of NANBIOSIS, has received an award at EIT Health Spain event held this month at the PCB, Barcelona.  The awards have been organized by the Spanish node during 2016 and are part of the financing initiatives of the EIT Health accelerator. Professor Engel participated in the category of ‘Proof of Concept (PoC)” that recognises projects and business ideas that are in stages prior to the creation of the company and projects that are participating in acceleration programs in health. Elisabeth won a prize funded with 25.000 € for Dermoglass, the smart dressing for[...]

13 Sep

Elisabeth Engel stimulating scientific talent in the Barcelona International Youth Science Challenge
Elisabeth Engel stimulating scientific talent in the Barcelona International Youth Science Challenge (BIYSC)

Dr. Engel, Scentific Director of Unit 5 of NANBIOSIS, participated in the Barcelona International Youth Science Challenge (BIYSC) held in Barcelona from July 11th to 22nd 2016. Ms. Elisabeth gave the lecture “Biomaterials beyond a simple template”, introducing the students to the breakthrough in the medical and social  field of obtaining a synthetic biomaterial that eludes the need of cell therapy or the application of morphogens and growth factors. The research group led by Elisabeth Engel hosted one of the projects of this programme: “Instructive Biomaterials for Regenerative Medicine” dealing with replacement or regeneration of human cells, tissues or organs,[...]

05 Jul

Elizabeth Engel, Scientific Coordinator of Unit 5 of NANBIOSIS: “Our research has opened the door to the regeneration of the nervous system by biomaterials”
Elizabeth Engel, Scientific Coordinator of Unit 5 of NANBIOSIS: “Our research has opened the door to the regeneration of the nervous system by biomaterials”

The CIBER-BBN research group Biomaterials for Regenerative Therapies, which coordinates Unit 5 of NANBIOSIS develops various lines of research on biomaterials for regenerative therapies, especially focusing on the design and fabrication of scaffolds for tissue regeneration. They are working with polymers, hydrogels and compounds that can be manufactured using different techniques such as electrospinning to make 3D printing matrices or scaffolding. Applications are diverse, such as bone regeneration, neuronal, skin or cell therapy. The group has recently presented the results of a project focused on the development of implants for the regeneration of nerve tissue with very promising results. T[...]

U5-Rapid-Prototyping-Unit
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

  • Scientific Coordinator: Dr. Santi Sala sala@icmab.es
  • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
  • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
  • Phone: +34 935 801 853
  • Fax: +34 935 805 729
  • Web: ICMAB
ICMAB CSIC
Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana, current director of NANOMOL Group, gathers several laboratories to perform the mission of this facility: the characterization, development and large-scale production ofmolecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure.
This unit is composed of the equipment and the scientific and technical personnel to develop and apply efficient, robust and green technologies based on the use of supercritical fluids (or dense gases), such as compressed CO2. The main activity of this unit is focused on the production of pure micro- and nanoparticulate active therapeutic ingredients and passive or active therapeutic nanoconjugates (vesicles, liposomes, nanosuspensions, micro- and nanostructured polymeric particles), as well as porous matrices of biocompatible polymers for tissue engineering or implants. The unit has also instruments and the necessary know-how to undertake nanostructuring of molecular biomaterials in films and surfaces, with application in the development of new biomedical devices. The facilities are equipped with laboratory and pre-pilot scale plants, high pressure phase analyzers and analytical instrumentation for micro- and nanoparticle physico-chemical characterization (particle size distribution, particle concentration, particle morphology and stability, Z-potential). One of the singularities of this unit is that counts with plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
 
U6. Services & Rates

News U6

16 May

Unit 6 of NANBIOSIS-ICTS Biomaterials processing and Nanostructuring at ICMAB-CSIC received the visit of high school students

A group of 22 students from the high school La Serra (Mollerusa) visited the Biomaterials and Nanostructuring Unit of NANBIOSIS,  at the Institute of Material Science of Barcelona of CSIC. The visit was an activity within the Nanoscience and Nanotechnology festival 10alamenos9  in which ICMAB participates. The students were guided through the labs by Amable Bernabé, technical responsible of U6, who explained them about nanotechnology, NANBIOSIS-ICTS research infrastructure and the different techniques available at “Biomaterials processing and Nanostructuring Unit”.[...]

15 May

NMR signal enhancement of >50 000 times in fast dissolution dynamic nuclear polarization

Jaume Veciana, Scientific Director of NANBIOSIS-ICTS has participated  in the research results published in the journal Chemical Communication, wich reports the synthesis and the study of a novel mixed biradical with BDPA and TEMPO radical units that are covalently bound by an ester group (BDPAesterTEMPO) as a polarizing agent for fast dissolution DNP. The biradical exhibits an extremely high DNP NMR enhancement of >50000 times, which constitutes one of the largest signal enhancements observed so far, to the best of our knowledge. Some of the researchs were made taking advantage of the characterization facilities provided by ICTS NANBIOSIS. For more information: L. F.[...]

11 May

NANOMOL group, coorditator of Unit 6 of NANBIOSIS has authored 26% of the scientific articles of ICMAB in NATURE

The Nature Index takes into account the published scientific articles from 1 February 2016 to 31 January 2017.  This index is elaborated annually based on the affiliations of the authors of scientific articles published in a selection of 68 high-quality journals (http://www.natureindex.com/faq#journals) CSIC appears as the first Spanish research centre in this ranking and occupies position number 38 in the global ranking of 500 research centres worldwide, while ICMAB occupies the first position within the CSIC centre, taking into account the corrected index WFC that shares the work between the different co-authoring institutions and corrects for the overrepresentation of som[...]

23 Apr

NANBIOSIS Scientific Director Dr. Jaume Veciana received a Mention of Honor for his dedication to NANBIOSIS

On April 22, Dr. Jaume Veciana received a Mention of Honor from the current President of Extremadura, Guillermo Fernández Vara, during the celebration of the X Anniversary of the Center for Minimally Invasive Surgery “Jesus Usón” for his commitment, effort and dedication in the creation of the Singular Scientific Technological Infrastructures (ICTS) NANBIOSIS, in collaboration with the Center for Biomedical Research Center in Bioingeneering, Biomaterials and Nanomedicine (CIBER-BBN). Further information:[...]

06 Apr

MATBIO 2017
Materials for Biomedical Applications Scientific School (BIOMAT-2017)

Registration is now open for the Scientific School on Materials for Biomedical Applications (BIOMAT-2017) that will take place on 19th-22nd of June 2017 in the UAB Campus (Barcelona). This school is organized by ICMAB-CSIC and it is included in the Severo Ochoa activities of the Institute. The school is addressed to last year undergraduate, master and PhD students, who are interested in the development of materials for biomedical applications. The aim of the school is to present the design, development and application of new materials for a wide range of biomedical applications. The school includes lectures from international and loca[...]

21 Dec

Validation of a drug for foot ulcers in collaboration with Cuba
Validation of a drug for foot ulcers in collaboration with Cuba

Nanomol, (Unit 6 of NANBIOSIS) has announced in Cuba that the process of clinical validation of a new drug developed and patented in collaboration with Center of Genetic Engineering and Biotechnology of Cuba, integrated in BioCubaFarma, has been initiated. The new drug is designed to improve the healing of foot ulcer in diabetics and could be on the market in five years. The collaboration of the Center for Genetic Engineering and Biotechnology of Cuba with Nanomol, coordinating group of Unit 6 of NANBIOSIS, began in 2010. Cuban researchers had developed an effective product in wound healing in diabetics but t[...]

16 Dec

Lipid-based Nanovesicles for Nanomedicine
Lipid-based Nanovesicles for Nanomedicine

Jaume Veciana and Nora Ventosa, Scientific Directors of Unit 6 of NANBIOSIS together with other researchers from NANOMOL group, coordinator of Unit 6 of NANBIOSIS, has recently published an interesting review article in the journal Chemical Society Reviews. This review presents the large plethora of lipid-based nanovescicles available nowadays, focusing on a new generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, it also extensively review the current approaches exploited for L-NV production. T[...]

22 Nov

Extraordinary doctoral award
Extraordinary doctoral award

Ingrid Cabrera, member of the NANOMOL group that coordinates Unit 6 of NANBIOSIS, has obtained the extraordinary doctoral award from the Universitat Autònoma de Barcelona for her thesis “Nanovesicle-bioactive conjugates to be used as nanomedicines, prepared by a one-step scalable method Using CO₂-expanded solvents“. This thesis was directed by Jaume Veciana, Scientific Director of NANBIOSIS and Nora Ventosa, Scientific Director of Unit 6 of NANBIOSIS. The main objectives of the  PhD Thesis of Dr. Ingrid Cabrera were the preparation and study of multifunctional nanovesicle based nanoformulation of alfa-galactosidase for the treatment of Fabry desease as well as of another multifunctiona[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U7. Nanotechnology Unit

Ciber bbn

U7. Nanotechnology Unit

  • Scientific Director: Prof. Josep Samitier jsamitier@ub.edu
  • Scientific Coordinator: Dr. Isabel Oliveira ioliveira@ibecbarcelona.eu
  • Scientific Coordinator: Dr. Mateu Pla Roca mpla@ibecbarcelona.eu
  • Entities: Intitute of Bioengineering of Catalonia (IBEC)
  • Address: C/Baldiri I Reixac, 10, 08028, Barcelona, Spain
  • Phone: +34 934 037 138
  • Web: IBEC
IBEC
Order request

Description

The Nanotechnology Platform is part of the institute’s long-term strategic plan to create new Core Facilities in nanofabrication and bionanocharacterization. Currently, the platform is an accessible and versatile research facility featuring 150m2 of class 10,000 cleanroom space and laboratories offering state-of-the-art equipment for the fabrication and characterization of micro- and nanodevices and structures. Our aim is to facilitate advanced research by providing services in the fields of nanoscience and nanotechnology for all academic and industrial researchers. Some of the many areas of application include nanobioengineering, BioMEMS, materials science, tissue engineering, optic and biomaterials. IBEC’s Nanotechnology Platform offers scientific and technological support that includes the design, development and analysis of devices, materials, and processes, so that academic researchers and companies alike may use the platform to develop their innovative ideas.

News U7

19 Dec

NANBIOSIS in three projects funded by CaixaIMPULSE.
NANBIOSIS in three projects funded by CaixaIMPULSE

La Caixa has just presented the twenty projects selected by CaixaImpulse in a call with more than 70 proposals from different research centres, hospitals and universities. CaixaImpulse is an initiative unique in Spain that aims to boost research in biotechnology and life sciences to develop projects that generate value in society. Among the selected projects there are two coordinated by NANBIOSIS researchers: Pseudomonas aeruginosa diagnosis led by Miriam Corredor Sánchez (Unit 2 of NANBIOSIS) and ISCHEMSURG, led by Monica Mir (Unit 7 of NANBIOSIS). In addition, the project ExoLiver, in which participates Rosa Villa and the research group coordinating Unit 8[...]

07 Apr

Josep Samitier, Scientific Director of Unit 7 of NANBIOSIS_named new president of ACER
Josep Samitier, Scientific Director of Unit 7 of NANBIOSIS, was named new president of ACER

Associació Catalana d’Entitats de Recerca (ACER) is an independent association of more than 40 institutions in Catalonia – including CRG, IRB, ICFO, IBEC, VHIR and IDIBAPS – which conduct research as their principal mission. The collective vocation of the associated organisations is to contribute to defining the scientific and research priorities and policies in Catalonia, and to optimise their management and implementation in their respective areas  by representing its associated centres, encouraging collaboration and the coordinated exchange of information, promoting synergies with similar agencies related to local, national or international research, and contributing to the improvement of scientific understanding in[...]

U7-Nanotechnology Unit
Read More

U8. Micro – Nano Technology Unit

Ciber bbn

U8. Micro – Nano Technology Unit

  • Scientific Coordinator: Dr. Gemma Gabriel gemma.gabriel@imb-cnm.csic.es
  • Entities: Instituto de Microelectrónica de Barcelona – Cenro Nacioal de Microelectrónica (IMB-CNM, CSIC)
  • Address: Campus UAB, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 947 700 ext. 1208
  • Web: IMB – CNM, CSIC

 

CNM CSIC
Order request

Description

This Micro-Nano Technologies Unit is located in the Microelectronic Institute of Barcelona, (IMB-CNM, CSIC) which is the largest installation with micro-nano technologies facilities in Spain. Its 1500 m2 Clean Room classes 10 to 10,000 are considered as Singular Scientific-Technical Infrastructure (ICTS). The platform is coordinated by Dr. Jordi Aguiló and this unit is based on a CVD (chemical vapor deposition) equipment for the controlled growth of carbon nanotubes (CNTs).
The integration of the unit in the clean room facilities of the IMB-CNM enables a complete range of processes (thermal processes and CVD, metallization, photolithography, dry and wet etching) for the complete fabrication of MNBS devices. So, from the platform it is supported the whole MNBS fabrication steps: the customization of the technology needed, the design of the devices, the complete fabrication process, their encapsulation, the characterization and test up to the technological support on the experimental uses.

News U8

19 Dec

Extraordinary doctoral award to Anton Guimerà Brunet
Extraordinary doctoral award

Anton Guimerà Brunet, member of the GBIO group that coordinates Unit 8 of NANBIOSIS, has obtained the extraordinary doctoral award from the Universitat Autònoma de Barcelona for his thesis “Novel methods and tools for corneal barrier function assessment through non-invasive impedance measurements”. This thesis was directed by Rosa Villa, Scientific Director of Unit 8 of NANBIOSIS. The thesis covers aspects of basic research as applied, reaching the transference to the biomedical industrial sector and solving a need in the ophthalmological diagnosis to be able to quantify the degree of corneal permeability. This innovation also includes the development of a flexib[...]

19 Dec

NANBIOSIS in three projects funded by CaixaIMPULSE.
NANBIOSIS in three projects funded by CaixaIMPULSE

La Caixa has just presented the twenty projects selected by CaixaImpulse in a call with more than 70 proposals from different research centres, hospitals and universities. CaixaImpulse is an initiative unique in Spain that aims to boost research in biotechnology and life sciences to develop projects that generate value in society. Among the selected projects there are two coordinated by NANBIOSIS researchers: Pseudomonas aeruginosa diagnosis led by Miriam Corredor Sánchez (Unit 2 of NANBIOSIS) and ISCHEMSURG, led by Monica Mir (Unit 7 of NANBIOSIS). In addition, the project ExoLiver, in which participates Rosa Villa and the research group coordinating Unit 8[...]

06 Dec

The Journal “Diario Médico” awards the project "Liver on a chip" participated by researchers of U8 of NANBIOSIS
The Journal “Diario Médico” awards the project “Liver on a chip” participated by researchers of U8 of NANBIOSIS

The 15th edition of  “Best Ideas 2016” by Diario Médico, has awarded the “Liver on a Chip” project, coordinated by Rosa Villa, Scientific Coordinator of Unit 8 of NANBIOSIS. “Liver on a chip” is a microfluidic camera that simulates hepatic microcirculation and will serve as a tool for in vitro studies and diagnostics of cell function, pharmacology, toxicity and personalized medicine. The device could be applicable to any other biomedical research in That the vascular system has relevance (liver, kidney, cardiovascular and others). This project was already recognized last July with the second prize of the category of innovation in[...]

22 Nov

Graphene will revolutionize the world
Graphene will revolutionize the world

Elisabet Prats, researcer of the GBIO Group, coordinator of Unit 8 of NANBIOSIS, participated in the  #ImproCiencia dissemination event, held on November 16 in Madrid organized by CIBER. Elisabet presented the Neurographene project as a monologue and explained how they are using graphene for Measure the electrical activity of the brain. Based on the latest microfabrication technologies, the devices consist of graphene microsensor matrices mounted on flexible polymer substrates that adapt to the surface morphology of the brain. Each sensor detects tiny changes in the electrical activity around it. Thus, the electrical activity generated by the neurons is detected as[...]

08 Jul

Pablo Laguna and Jordi Aguilo, Scientific Directors of the Units 27 and 8 of NANBIOSIS participate in the European program Remote Assessment
Pablo Laguna and Jordi Aguilo, Scientific Directors of the Units 27 and 8 of NANBIOSIS participate in the European program Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

RADAR-CNS is an important European research program supported by the Innovative Medicines Initiative (IMI) focused to develop new ways of monitoring patients affected by major depression, epilepsy and multiple sclerosis, with the use of wearable technology and smart mobile phones. This program brings together experts from various disciplines in clinical research, engineering, computer and data analysis, as well as health services. RADAR-CN aims to improve symptoms and quality of life of patients and treatment of these and other chronic diseases. This program is jointly led by King’s College London and the pharmaceutical company Janssen and is funded by the Innovative Medicines[...]

14 Apr

Nanbiosis_U8_Graphene Flagship for Biomedical Tecnologies
Graphene Flagship for Biomedical Tecnologies – Kick off meeting April 11-14 Barcelona

On April, 11-12 took place in Barcelona the kick off meeting of the new Graphene Flagship Work Package devoted to Biomedical Technologies, one emerging application area for graphene and other 2D materials. The Kick-off event, was co-organised by Dr. Rosa Villa (CNM-IMB-CSIC, CIBER-BBN) Scientific Coordinator of Unit 8 of NANBIOSIS (in the center of the first row in the photo). More than 35 Scientifics from 14 research groups attended to the meeting The Graphene Flagship, the EU’s biggest ever research initiative, involves the coordination research of over 150 partners from more than 20 European countries withing a timeframe of 10[...]

11 Mar

Nanbiosis_U8 - Biomedical applications of graphene, Elisabet Prats in Informativos.net
Biomedical applications of graphene: Elisabet Prats in Informativos.net

[Elisabet Prats in Informativos.net] As a science disseminator, Elisabet has recently appeared in media and forums explaining the progress made by her research group in the European project Graphene Flagship. For example, a graphene sensor to detect brain electrical activity, successfully presented at Mobile World Congress. Elisabet clearly explains “We are able to measure the electrical signals of the brain with graphene, graphene due to its versatility, allows the reduction in size of the sensors, giving much more information to the doctor” and describes a future in which “we shall control mechanical arms with brains implants”.[...]

24 Feb

Nanbiosis_Unit8-Graphene sensors presented in Mobile World Congress Barcelona 2016
Graphene sensors partially developed in UNIT 8 of NANBIOSIS are presented at the Mobile World Congress in Barcelona

These devices, that can detect the electrical activity of the brain, are currently being tested in animals by measuring their brain activity using  Graphene transitors and could have therapeutic applications, as well as allowing the design of new brain-machine interfaces.[...]

U8-Micro-Nano Technology Unit
Read More

U9. Synthesis of Nanoparticles Unit

Ciber bbn

U9. Synthesis of Nanoparticles Unit

    • Entities: Institute of Nanoscience of Aragón (INA)
    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
    • Phone: 34 976 761000 ext. 3496
Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.
Order request

Description

This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience of Aragón (INA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.

News U9

18 May

Platform2nano research by Víctor Sebastián, (Unit 9 of NANBIOSIS) awarded Marie Skłodowska-Curie

The Platform2nano research project (2012-2016) has just been awarded a second prize in the “Contribution for a better society” category, at the “Mobility Takes Research Further” conference organized by Marie Skłodowska-Curie actions (MSCA 2017) in the framework of the Presidency of Malta of the Council of the European Union. More than 195 researchers from 30 nationalities who have developed their scientific work through the prestigious Marie Skłodowska-Curie Scholarships were presented to these awards. The project “Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applications” in which participate the researchers Manuel Arruebo, Laura Usón, Isabel Ortiz[...]

12 May

Nanotechnology and biomedical applications. Gene therapy

Yesterday, at the University of Zaragoza, Prof. Nuria Vilaboa (CIBER-BBN– Hospital Universitario de La Paz) gave a talk  on “Nanotechnology and biomedical applications. Gene therapy“. The event was organized by Manuel Arruebo II Institute of Nanoscience of Aragon), researcher of the coordinating group of Unit 9 of NANBIOSIS. In recent years, a multitude of materials of nanometric size have been explored, which because of their small size have properties that give them a great attraction for a wide range of biomedical applications. Prof. Vilaboa reviewed gene therapy technology, where materials at  nanoscale offer interesting alternatives.[...]

20 Apr

J. Santamaría, U9 NANBIOSIS gets 2.5M € to develop a revolutionary cancer treatment

Jesús Santamaría, Scientific Director of Unit 9 of NANBIOSIS, has obtained, for the second time in six years, an ERC Advanced Grant, one of the most prestigious and extremely competitive European research grants, restricted to senior researchers with a research trajectory of high quality for more than ten years. The CADENCE (Catalytic Dual-Function Devices Against Cancer) project will be financed by the EU with 2.5M € to work for five years with a powerful team: four own researchers and seven others to be selected from candidates from all over the world. With this project the researchers propose a revolutionary cancer[...]

22 Mar

Three Scientifics of NANBIOSIS in University of Zaragoza ERC 10 years celebration event

2017 is the year of the X Anniversary of the European Research Council (ERC), created to finance research projects of excellence at the frontier of knowledge of any scientific discipline. The structure of the ERC consists of an autonomous scientific council made up of 22 distinguished scientists supported by an executive agency that is responsible for implementing the program, organizing the evaluation and managing the aid. The University of Zaragoza, hosting three units of NANBIOSIS, joined the celebrations with an event that took place on March 15. Among the assistants, three Scientists of NANBIOSIS recognized with ERC: Jesús Santamaría, Scientific[...]

13 Feb

Titania-coated gold nanorods with expanded photocatalytic response

New communication in the Journal Nanoscale, from the Royal Society of Chemistry by NFP Group, coordinator of Unit 9 of NANBIOSIS. Jesús Santamaría, Scientific Director of Unit 9 of NANBIOSIS together with other authors of the Nanostructured Films and Particles (NFP) Group, coordinator of Unit 9 of NANBIOSIS, has published on February 7, 2017, a Communication in the Journal Nanoscale, from the Royal Society of Chemistry. The syntheses of materials during the research have been performed by the Platform of Production of Biomaterials and Nanoparticles of the NANBIOSIS ICTS, more specifically by the Nanoparticle Synthesis Unit, as stated in the publication. Gold[...]

17 Jan

Multifunctional biomaterials and nanomaterials
Multifunctional biomaterials and nanomaterials: the new technological revolution.

CaixaForum Zaragoza, Wednesday, January 18th, 2017 at 7:00 pm: talk by Jesús Santamaría, Scientific Director of Unit 9 of NANBIOSIS, within the Conference Cycle: Technology, the permanent revolution Nanotechnology is the application of nanoscience and, in its modern conception, implies having the ability to design nanomaterials for a specific purpose and to control the manufacturing processes that allow them to have the desired characteristics (composition, size, shape, surface characteristics). This talk presents the developments in nanotechnology as a true technological revolution. The general concepts and the influence of nanotechnology in our lives shall be discussed with examples of recent advances,[...]

24 Nov

Award to research with micronanotechnology.
Award to research with micronanotechnology.

The Royal Spanish Academy of Engineering has awarded a medal to Víctor Sebastián Cabeza, researcher of the group “Nanostructured Films and Particles”, which coordinates Unit 9 of NANBIOSIS. The prize has been awarded in recognition of his work in designing a wide variety of micro-reactors to produce nanomaterials in a controlled and successful manner, reducing time and costs, with applications in Biomedicine, catalysis or energy processes. Dr Víctor Sebastián also received the prestigious Fulbright scholarship in 2009 to carry out a postdoctoral research at the Massachusetts Institute of Technology (MIT) on nanomaterials and its development in microfluidics and in 2014[...]

21 Nov

Three Universities among the 200 best in the world in science, hosting 4 Units of NANBIOSIS.
4 Units of NANBIOSIS hosted in three Universities among the 200 best in the world in science.

The University of Zaragoza is one of the 200 best universities in the world in science research, according to the latest Shanghai ranking of 2016 in a specific analysis by macro areas. In order to elaborate this ranking by macroareas indicators such as the number of students and professors who have obtained the Nobel prize or Fields medal, the number of researchers highly cited in the scientific literature, the number of scientific articles indexed in the Science Citation Index and the Percentage of articles published in the most cited 20% scientific journals are used. Only six Spanish universities are among[...]

U9-Synthesis of Nanoparticles Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

  • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
  • Scientific Coordinator: Dr. Jesús Ciriza Astrain jeciriza@gmail.com
  • Entities: Universidad del País Vasco (UPV/EHU)
  • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
  • Phone: +34 945 013091
  • Fax: +34 945 013040
  • Web: NANOBIOCEL UPV/EHU
UPV-EHU
Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

News U10

16 May

New gelatine devices that mimic the body’s activity in bone regeneration

The NanoBioCel Group, Coordinator of Unit 10 of NANBIOSIS has led the development of new scaffolds (such as burns, trauma or tumour extractions), to regenerate critical bone defects that, in addition to physical support, offers the opportunity to release growth factors temporarily replacing the bone matrix and aiding the regeneration of bone tissue. In order [...]

18 Apr

New treatments for degenerative diseases of the retina

The final meeting of the TERET project took place last March, an initiative within the RETOS public-private collaboration initiative of the Ministry of Economy, Industry and Competitiveness funded with almost € 1 million. The project has been carried out over the past three years to develop new treatments for degenerative diseases of the retina, focusing [...]

09 Feb

bioprinted human cells
3DBio-impression systems and bio-ink for the regeneration of cartilage and bone

The Nanobiocel Group, coordinator of Unit 10 of NANBIOSIS participate in a public-private collaborative project to reach clinical application in the regeneration of osteochondral lesions, which mainly affect the knee and ankle joints. The new project is funded by the Challenges-Collaboration program of the Ministry of Economy, Industry and Competitiveness. It has a budget of [...]

18 Jan

Nanomedicine in B·Debate Fighting Blindness by Unit 10 of NANBIOSIS
Nanomedicine in B·Debate Fighting Blindness by Unit 10 of NANBIOSIS

The recent published Newsletter of Institut of Màcula and the Barcelona Màcula Foundation: Research for Vision reported about the forum  B·Debate Fighting Blindness. Future Challenges and Opportunities for Visual Restoration, September 6-7 , that gathered more than thirty experts in the different areas related with blindness. The second Session, about Nanotechnology and Nanomedicine, was chaired [...]

13 Jan

Nanbiosis U10 Micro and nano capsules that will increase the effectiveness and precision of medicine.
Micro and nano capsules that will increase the effectiveness and precision of medicine.

José Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS and members of NANOBIOCEL group, which coordinates Unit 10 of NANBIOSIS, explain for the TEKNOPOLIS program of EiTB, the first communication group in the Basque Country, the development of micro and nanocapsules, gels and scaffolds to solve the problems of administration of new drugs. The [...]

02 Dec

"It is necessary to increase our relationship with European research groups" by José Luis Pedraz - U10 of NANBIOSIS
“It is necessary to increase our relationship with European research groups” by José Luis Pedraz – U10 of NANBIOSIS

Last Sunday, November 27, the Newspaper of Álava published a special supplement with the title “ALAVA 2020”. It contained an article by José Luis Pedraz (Scientific Director of Unit 10 of NANBIOSIS) According to Dr. Pedraz, group leader of the CIBER-BBN NANOBIOCEL group, in the next future, important challenges with new technologies will allow a [...]

04 Oct

Midyear meeting in Vitoria of European project DRIVE
Midyear meeting in Vitoria of European project DRIVE

CIBER-BBN participates in the project through NanoBioCel group, led by professor José Luis Pedraz Muñoz, Scientific Director of Unit 10 of NANBIOSIS, working on the optimization of formulations to be included in a bioartificial organ. José Luis Pedraz Munoz and Jesus Izco coordinator of NANBIOSIS have participated in the meeting held in Vitoria on 3 [...]

03 Jun

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.
Nanbiosis in the 2ª General Assambly of DRIVE project, Venice (16th-17th 2016)

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation  of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of  DRIVE project, held in Venice, May 16th-17th 2016. The second General Assembly of European project DRIVE “DIABETES-REVERSING-IMPLANTS FOR ENHANCED VIABILITY AND LONG TERM EFFICACY”, took place [...]

26 Apr

Nanbiosis_U10_Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids
Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids

Jose Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS and Ramon Eritja (CIBER-BBN) have participated in the entrapment of cationic nioplexes in supramolecular hydrogels and the use of these materials for transfecting cells. This work is focused on entrapping cationic nioplexes within supramolecular hydrogels based on N-protected phenylalanine. To modulate the supramolecular hydrogel diffusion [...]

03 Mar

Nanbiosis_Unit8-Drive Project-Improving transplant pancreatic cells_Dr. Jose Luis Pedraz
Drive Project: Improving transplant pancreatic cells

José Luis Pedraz, Scientific Director of the Unit 10: Drug Formulation of NANBIOSIS explained DRIVE European project in the third edition of Diabetes Experience Day, diabetic patients meeting that gathered 1500 people in Madrid. The DRIVE project, in which participate fourteen partners from seven European countries, among which is the CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment diabetes.

[...]

U10-Drug Formulation
Read More
Nanbiosis